| 1/2 | US=67 / Biol/Mol Thiagalingam S, Faller DV. The cancer epigenome: cann it be targeted for therapy?. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 97-113. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; EPIGENOMA; METILACAO DO DNA; DNA METIL TRANSFERASE; HISTONA ACETILTRANSFERASE; HISTONA-DESACETILASE; CODIGO DE HISTONAS; CODIGO EPIGENOMICO ATIVA; CODIGO EPIGENOMICO SILENCIADO; INIBIDOR DE HISTONA-DESACETILASE; TERAPIA DO CANCER |
| 2/2 | US=16 / Urologia Kortenhorst MSQ, Carducci MA, Shabbeer S. Therapeutics: differentiation agents and epigenomic therapies. In: Chung LWK, Isaacs WB, Simons JW. Prostate cancer: biology, genetics, and the new therapeutics. 2ª ed. New Jersey: Humana Press, 2007. p. 411-43. (Contemporary Cancer Research) ISBN 978-1-58829-696-2. CANCER DE PROSTATA; TERAPEUTICA; AGENTES DE DIFERENCIACAO; TERAPIA EPIGENOMICA; ACETILACAO; MODIFICACAO DA CROMATINA; REMODELAMENTO DA CROMATINA; ENSAIOS CLINICOS; EPIGENETICA; HISTONA ACETIL TRANSFERASE; CODIGO DE HISTONAS; INIBIDOR DE HISTONA-DESACETILASE; METILACAO; INIBIDOR METIL TRANSFERASE |